| 55.21 1.38 (2.56%) | 04-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 68.5 | 1-year : | 80.01 |
| Resists | First : | 58.65 | Second : | 68.5 |
| Pivot price | 52.56 |
|||
| Supports | First : | 52.22 | Second : | 48.25 |
| MAs | MA(5) : | 53.88 |
MA(20) : | 52.21 |
| MA(100) : | 59.76  |
MA(250) : | 56.01 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 81.2 |
D(3) : | 81.5 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 72.06 | Low : | 45.74 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TECH ] has closed It is unclear right now based on current values. 50.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 56.97 - 57.19 | 57.19 - 57.41 |
| Low: | 53.31 - 53.57 | 53.57 - 53.82 |
| Close: | 54.79 - 55.19 | 55.19 - 55.58 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Wed, 08 Apr 2026
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Wed, 08 Apr 2026
Sivik Global Healthcare LLC Takes $2.65 Million Position in Bio-Techne Corp $TECH - MarketBeat
Wed, 08 Apr 2026
Why Bio-Techne Stock Is Dropping Hard Today - TipRanks
Tue, 07 Apr 2026
How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story - simplywall.st
Mon, 06 Apr 2026
242,016 Shares in Bio-Techne Corp $TECH Acquired by Tudor Investment Corp ET AL - MarketBeat
Wed, 25 Mar 2026
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 156 (M) |
| Shares Float | 155 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 113.8 (%) |
| Shares Short | 12,350 (K) |
| Shares Short P.Month | 11,310 (K) |
| EPS | 0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.89 |
| Profit Margin | 6.6 % |
| Operating Margin | 19.6 % |
| Return on Assets (ttm) | 6.5 % |
| Return on Equity (ttm) | 3.9 % |
| Qtrly Rev. Growth | -0.5 % |
| Gross Profit (p.s.) | 5.17 |
| Sales Per Share | 7.79 |
| EBITDA (p.s.) | 2.11 |
| Qtrly Earnings Growth | 9.1 % |
| Operating Cash Flow | 249 (M) |
| Levered Free Cash Flow | 261 (M) |
| PE Ratio | 104.16 |
| PEG Ratio | 0 |
| Price to Book value | 4.27 |
| Price to Sales | 7.08 |
| Price to Cash Flow | 34.64 |
| Dividend | 0.07 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|